Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 is a new market research publication announced by Reportstack. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

GSK’s Tykerb (lapatinib ditosylate monohydrate) is a small-molecule inhibitor of the intracellular tyrosine kinase domain of EGFR and HER2. Tykerb was approved by the FDA in 2007, and by the European Medicines Agency (EMA) in 2008, for use in locally-advanced or metastatic breast cancer, in combination with Xeloda (capecitabine). In 2010, the FDA and EMA approved Tykerb for use in HR positive locally advanced or metastatic breast cancer in combination with letrozole.

Scope

- Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tykerb including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tykerb for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tykerb performance
- Obtain sales forecast for Tykerb from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Complete report available @ http://www.reportstack.com/product/178907/tykerb-her2-positive-breast-cancer-forecast-and-market-analysis-to-2023.html

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 - http://www.reportstack.com/product/178908/neratinib-her2-positive-breast-cancer-forecast-and-market-analysis-to-2023.html

Contact:

Debora White
debora@reportstack.com
Reportstack Market Research